AzTrials
AzTrials

Diabetes Mellitus, Type 1DIA-BATNCT03695731

Influence of Diabetic Neuropathy on Activation of Brown Adipose Tissue

A study testing cold induced activation of brown adipose tissue in people with Diabetes Mellitus, Type 1, run by Doctor Giacomo Gastaldi at 1 site in Switzerland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Influence of diabetic neuropathy on cold induced brown adipose tissue in type 1 diabetic patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes Mellitus, Type 1
What is being tested?
cold induced activation of brown adipose tissue
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteSwitzerland
Study dates
15 Oct 2018to 15 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Type 1 diabetes
  • Patients who can understand the issue of this study and who are able to decide for themselves whether or not to participate in the study.
  • Adult patient (>18 years old)
  • Informed Consent form signed
  • Differentiated inclusion:
  • Group A: absence of neuropathy
  • Group B: significant neuropathy

Who cannot join

  • Treatment with beta-blockers
  • Alcohol consumption(> 50 gr/week)
  • Allergy to 18F-FDG
  • Participation in another clinical study (4 weeks prior to entry) that may influence the activity of brown adipose tissue
  • Pregnancy
  • Exposure to ionizing radiation greater than or equal to 5 mSv during the year preceding the PET-RMI planned in the study

Trial locations and contacts

1 site in 1 country.

Giacomo Gastaldi, Dr. contact

+41795533638

giacomo.gastaldi@hcuge.ch

Switzerland1 site, 1 recruiting
  • Geneva University Hospital

    Geneva, 1205

    Giacomo Gastaldi, giacom.gastaldi@hcuge.ch

    Recruiting

Other trials in Switzerland

About this study

Influence of diabetic neuropathy on cold induced brown adipose tissue in type 1 diabetic patients.

Read the detailed description

The prevalence of type 1 diabetes has been steadily increasing for about 20 years. Despite therapeutic progress, between 20 and 65% of people with diabetes develop diabetic neuropathy, resulting in increased morbidity and mortality.

Diabetic neuropathy is not limited to sensitive pain in the lower limbs. It also affects the fibres of the autonomic nervous system (ANS), which results in systemic complications, often disabling (erectile dysfunction, dysidrosis, gastroparesis, orthostatism, etc.) and a probable alteration in the body's thermogenic capacities, although this possibility has not been studied in humans. In rodents, it is possible to activate induced thermogenesis via central stimulation of the ANS or to inactivate it, which promotes the development of obesity and greater insulin resistance. This knowledge is based on cellular and animal models that have identified the bio-molecular mechanisms that give brown adipose tissue (BAT) the ability to dissipate energy in the form of heat.

Induced thermogenesis is mediated by decoupling proteins 1 (DCS-1) located on the mitochondrial inner membrane of the TAB. DCS-1 decouple oxidative phosphorylation from ATP production, dissipating the proton gradient. The activation of UCP1 is particularly influenced by the sympathetic system and more particularly by catecholamines which will bind to ß3 adrenergic receptors (Rß3). In humans, the persistence of active areas of TAB has recently been demonstrated by positron emission tomography (PET) imaging using a glucose analogue radiotracer, 18F-Fluoro-Deoxy-Glucose (18F-FDG), coupled with the scanner (CT). Recently, it has been shown that the use of 18F-FDG PET coupled with magnetic resonance (MRI) is equally effective in differentiating TAB from white fat tissue with less patient irradiation. The activity of the TAB is estimated using the measurement of SUV (standard uptake value) which represents the total glycolytic activity of the tissue and is also commonly referred to as the total metabolic volume. It has been shown in humans that TAB activity is inversely correlated with body mass index and age and positively correlated with exposure to cold and stress levels[6]. Among diabetics, the data are disparate but the spontaneous prevalence of TAB appears to be reduced compared to the general population (1.1% vs 7.5%). To date, no studies have investigated a possible link between the decrease in TAB activity observed in diabetics and the presence of autonomic neuropathy, which is a common and often under-diagnosed complication of diabetes.

The main purpose of this study is to evaluate whether the activity and distribution of TAB in patients with diabetes is influenced by the presence of diabetic neuropathy. On the other hand, if the existence of diabetic neuropathy influences energy expenditure in the event of exposure to cold. Finally, whether any differences in the activity and distribution of TAB could be related to changes in the central nervous system.

The investigators plan to include a total of 24 patients with type 1 diabetes and separate them into 2 groups: group A; no neuropathic complications and group B; presence of neuropathy. All patients will be characterized in terms of clinical, metabolic and energy expenditure. The activity of the TAB will be evaluated through the use of 18F-FDG PET/IRM imaging, after a cold stimulation protocol (refrigerated jacket) in order to activate the TAB in a homogeneous manner among the participants.

Being tested
cold induced activation of brown adipose tissue
Keywords
diabetes, brown adipose tissue, energy expenditure, glycemic control, neuropathy, 18F-FDG PET-RMI
Medical subject headings
Diabetes Mellitus, Type 1, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cold induced activation of brown adipose tissueProcedure or surgery

    cold exposure wearing a cold life jacket

Study groups in NCT03695731
Study groupRoleWhat they receive
Patients without NeuropathyExperimentalactivation of cold induced brown adipose tissue
Receives: Procedure: cold induced activation of brown adipose tissue
Patients with NeuropathyExperimentalactivation of cold induced brown adipose tissue
Receives: Procedure: cold induced activation of brown adipose tissue

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. brown adipose tissue activation

    PET- MRI measurement (SUVR)

    Measured: 120 minutes after cold exposure

Secondary outcomes (1)
  1. Energy expenditure

    indirect calorimetry measurement

    Measured: before and 120 minutes after cold exposure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2018
  2. Study start15 Oct 2018
  3. Primary completion15 Oct 2019 (estimated)
  4. Study completion15 Oct 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03695731
Sponsor's protocol ID
14-170 (PB_2018-00258)
Acronym
DIA-BAT
Status last verified
May 2019
First submitted
26 Sep 2018
Last updated
9 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing cold induced activation of brown adipose tissue in people with Diabetes Mellitus, Type 1, run by Doctor Giacomo Gastaldi at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Giacomo Gastaldi, Dr. (+41795533638, giacomo.gastaldi@hcuge.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

brown adipose tissue activation (time frame: 120 minutes after cold exposure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in